Fortrea (FTRE) to Release Quarterly Earnings on Monday

Fortrea (NASDAQ:FTRE) will likely be announcing its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of $0.36 per share and revenue of $703.22 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Fortrea Price Performance

Shares of NASDAQ FTRE opened at $14.88 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.18. The company has a market cap of $1.33 billion, a PE ratio of -4.35, a P/E/G ratio of 1.78 and a beta of 1.20. The business has a 50-day simple moving average of $17.45 and a two-hundred day simple moving average of $19.47. Fortrea has a fifty-two week low of $14.27 and a fifty-two week high of $41.02.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Fortrea from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Baird R W downgraded shares of Fortrea from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 6th. William Blair reiterated a “market perform” rating on shares of Fortrea in a research note on Friday, November 8th. Robert W. Baird cut Fortrea from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $28.00 to $25.00 in a research report on Friday, December 6th. Finally, TD Cowen lifted their price target on Fortrea from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating and eleven have assigned a hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.30.

Insider Transactions at Fortrea

In related news, CEO Thomas Pike sold 11,268 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.04, for a total value of $203,274.72. Following the completion of the transaction, the chief executive officer now directly owns 159,868 shares in the company, valued at $2,884,018.72. The trade was a 6.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 12,386 shares of company stock worth $219,751 over the last quarter. 0.12% of the stock is currently owned by insiders.

Fortrea Company Profile

Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.